search
Back to results

Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura

Primary Purpose

Henoch-Schönlein Purpura

Status
Recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Methylprednisolone
IVIG
other basic supportive treatment
Sponsored by
Children's Hospital of Fudan University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Henoch-Schönlein Purpura focused on measuring severe gastrointestinal involvement

Eligibility Criteria

2 Years - 16 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. both genders
  2. age between 2-16 years old
  3. IgA vasculitis with gastrointestinal involvement
  4. course of disease less than 2 months
  5. refractory to ordinary dosage of prednisolone (less than 2mg/kg/d)

Exclusion Criteria:

  1. patients with severe sepsis
  2. patients with central nervous system infection,
  3. patients with severe pneumonia
  4. patients with chronic infection (such as EBV, CMV, Tuberculosis)
  5. patients complicated by CKD who need renal replacement therapy
  6. patients suffering from severe central nervous system complications as intracranial hemorrhage or neuropathy

Sites / Locations

  • Children's Hospital of Fudan UniversityRecruiting
  • Children's Hospital of Shanghai
  • Shanghai Children's Medical Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Methylprednisolone group

IVIG group

Arm Description

In this group patients will be given Methylprednisolone pulse(15-30mg/kg/d) and continued with oral prednisolone (2mg/kg/d)

In this group patients will be given IVIG (2g/kg) and at the same time oral prednisolone (2mg/kg/d)

Outcomes

Primary Outcome Measures

sustained abdominal pain relief
no abdominal pain complaint and no abdominal tenderness

Secondary Outcome Measures

sustained abdominal pain relief
3 days after treatment part of the patients may fail the first assigned intervention and has to accept the alternative intervention and abdominal pain complaint and abdominal tenderness will be checked at 7 days after treatment
other treatment rather than assigned intervention
other treatment such as blood purification, the second methylprednisolone pulse, and immunosuppressant will be documented if the two interventions all failed
tolarable food type
what kind of food can be tolerant ( 0 fluid, 1 semi liquid, 2 solid )
the number of days of taking fasting
the number of days of taking fasting will be counted at the time of discharge
Drug-related side effects
Side effects associated with methylprednisolone and IVIG will be recorded
hypertension
systolic or diastolic blood pressure greater than or equal to 95% for the age, sex, and height of the patient is considered to have 1.hypertension otherwise 0. Blood pressure will be measured with mercury blood pressure monitor.
infection
different infection types should be specified
ocular hypertension
1.ocular hypertension 0. no ocular hypertension. Ocular hypertension will be defined as intraocular pressure of either eye is greater greater or equal to 21mmHg
steroid-related diabetes
1. with steroid-related diabetes 0. no steroid-related diabetes . Steroid-related diabetes will be defined as random blood sugar is greater than 11.1 mmol/l
cost of treatment
cost of treatment will be obtained from discharge fee list
The number of days in hospital
The number of days in hospital will be counted at the time of discharge

Full Information

First Posted
August 22, 2018
Last Updated
February 3, 2023
Sponsor
Children's Hospital of Fudan University
Collaborators
Shanghai Children's Hospital, Shanghai Children's Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT03647852
Brief Title
Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura
Official Title
Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 1, 2019 (Actual)
Primary Completion Date
October 30, 2024 (Anticipated)
Study Completion Date
October 30, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Children's Hospital of Fudan University
Collaborators
Shanghai Children's Hospital, Shanghai Children's Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
IgA vasculitis is relatively common in children,especially in Asian countries. Abdominal manifestation could be severe, including bleeding, pancreatitis,appendicitis and intestinal intussusception. Delayed diagnosis could be fatal and cause severe complications.Nowadays no guidelines for those with severe abdominal manifestations in China.However, the most used treatment is steroid. For those severe forms are methylprednisolone pulse, IVIG, immunosuppressants and blood purification. Given the fact that different strategies lead to different endings which varies in cost, adverse effect and clinical outcomes in different medical centers, it is necessary to give birth to a useful and feasible strategy. This clinical trial is a muti-center, randomized,controlled prospective study.Patients with gastrointestinal disease will be recruited in three children's medical centres in Shanghai and will be randomized to two groups: MP group and IVIG group. Cost effect and clinical outcomes will be evaluated. Blood purification will be evaluated as a remedy when MP and IVIG fail to cure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Henoch-Schönlein Purpura
Keywords
severe gastrointestinal involvement

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Methylprednisolone group
Arm Type
Experimental
Arm Description
In this group patients will be given Methylprednisolone pulse(15-30mg/kg/d) and continued with oral prednisolone (2mg/kg/d)
Arm Title
IVIG group
Arm Type
Active Comparator
Arm Description
In this group patients will be given IVIG (2g/kg) and at the same time oral prednisolone (2mg/kg/d)
Intervention Type
Drug
Intervention Name(s)
Methylprednisolone
Intervention Description
1.methylprednisolone pulse (15-30mg/kg/d) for 3 days with continued oral prednisolone(2mg/kg/d) 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given IVIG(2g/kg/d)as a change
Intervention Type
Drug
Intervention Name(s)
IVIG
Intervention Description
1. IVIG 2g/kg and oral prednisolone 2mg/kg/d 2.if the patients still complain abdominal pain and feel abdominal tenderness on the third day after intervention , patients would be given methylprednisolone pulse (15-30mg/kg/d) for 3 days
Intervention Type
Drug
Intervention Name(s)
other basic supportive treatment
Intervention Description
Omeprazole 0.8mg/kg.d.The maximum dose is less than 40mg per day Low molecular weight heparin calcium 50IU/kg.d
Primary Outcome Measure Information:
Title
sustained abdominal pain relief
Description
no abdominal pain complaint and no abdominal tenderness
Time Frame
3 days after treatment
Secondary Outcome Measure Information:
Title
sustained abdominal pain relief
Description
3 days after treatment part of the patients may fail the first assigned intervention and has to accept the alternative intervention and abdominal pain complaint and abdominal tenderness will be checked at 7 days after treatment
Time Frame
7 days after treatment
Title
other treatment rather than assigned intervention
Description
other treatment such as blood purification, the second methylprednisolone pulse, and immunosuppressant will be documented if the two interventions all failed
Time Frame
4 weeks after treatment
Title
tolarable food type
Description
what kind of food can be tolerant ( 0 fluid, 1 semi liquid, 2 solid )
Time Frame
2 weeks after treatment
Title
the number of days of taking fasting
Description
the number of days of taking fasting will be counted at the time of discharge
Time Frame
At the time of discharge
Title
Drug-related side effects
Description
Side effects associated with methylprednisolone and IVIG will be recorded
Time Frame
3 days after treatment
Title
hypertension
Description
systolic or diastolic blood pressure greater than or equal to 95% for the age, sex, and height of the patient is considered to have 1.hypertension otherwise 0. Blood pressure will be measured with mercury blood pressure monitor.
Time Frame
7 days after treatment
Title
infection
Description
different infection types should be specified
Time Frame
4 weeks after treatment
Title
ocular hypertension
Description
1.ocular hypertension 0. no ocular hypertension. Ocular hypertension will be defined as intraocular pressure of either eye is greater greater or equal to 21mmHg
Time Frame
7 days after treatment
Title
steroid-related diabetes
Description
1. with steroid-related diabetes 0. no steroid-related diabetes . Steroid-related diabetes will be defined as random blood sugar is greater than 11.1 mmol/l
Time Frame
3 days after treatment
Title
cost of treatment
Description
cost of treatment will be obtained from discharge fee list
Time Frame
4 weeks after treatment
Title
The number of days in hospital
Description
The number of days in hospital will be counted at the time of discharge
Time Frame
at the time of discharge

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: both genders age between 2-16 years old IgA vasculitis with gastrointestinal involvement course of disease less than 2 months refractory to ordinary dosage of prednisolone (less than 2mg/kg/d) Exclusion Criteria: patients with severe sepsis patients with central nervous system infection, patients with severe pneumonia patients with chronic infection (such as EBV, CMV, Tuberculosis) patients complicated by CKD who need renal replacement therapy patients suffering from severe central nervous system complications as intracranial hemorrhage or neuropathy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Li Sun, MD
Phone
+8618017590930
Email
lillysun@263.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Li Sun, MD
Organizational Affiliation
Children's Hospital of Fudan University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Wenyan Huang, MD
Organizational Affiliation
Shanghai Children's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital of Fudan University
City
Shanghai
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Li Sun, MD
Facility Name
Children's Hospital of Shanghai
City
Shanghai
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wenyan Huang, MD
Facility Name
Shanghai Children's Medical Centre
City
Shanghai
Country
China
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wei Zhou, MD

12. IPD Sharing Statement

Plan to Share IPD
Yes

Learn more about this trial

Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura

We'll reach out to this number within 24 hrs